sorafenib-resistant FLT3 mutants [plasma membrane]

Stable Identifier
R-HSA-9699530
Type
Set [DefinedSet]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
Literature References
PubMed ID Title Journal Year
28077790 FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

Levis, M, Nguyen, B, Williams, AB, Small, D, Brown, P, Li, L, Young, DJ, Ma, H

Oncotarget 2017
23392356 The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib

Yu, C, Albers, C, Verbeek, M, Duyster, J, Leischner, H, Illert, AL, von Bubnoff, N, Peschel, C

Leukemia 2013
23430109 Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD

Salerno, S, Zhu, X, Stewart, WK, Lasater, EA, Damon, LE, Shah, NP, Smith, CC, Lin, KC

Blood 2013
26108694 FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors

Shah, NP, Stecula, A, Smith, CC, Sali, A, Lin, K

Leukemia 2015
22858906 Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

Nguyen, B, Brown, P, Li, L, Levis, M, Williams, AB, Leahy, D, Small, D

Leukemia 2013
23969938 Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia

Mullighan, CG, Baker, SD, Rubnitz, JE, Zimmerman, EI, Orwick, S, Inaba, H, Neale, GA, Zatechka, DS, Buaboonnam, J, Enemark, EJ, Shurtleff, S, Wang, YD, Olsen, SR

Clin. Cancer Res. 2013
22504184 Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia

Perl, AE, Chin, CS, Schadt, EE, Shah, NP, Smith, CC, Kuriyan, J, Hunt, JP, Wang, Q, Salerno, S, Wang, S, Levis, MJ, Kasarskis, A, Zarrinkar, PP, Travers, KJ, Damon, LE

Nature 2012
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cite Us!